Live Breaking News & Updates on Biosimilar Monoclonal Antibodies Historic Market|Page 9

Stay updated with breaking news from Biosimilar monoclonal antibodies historic market. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adalimumab Biosimilar Effective, Safe for Inflammatory Bowel Disease Patients in China

This new research opens the door for further biological agent use in IBD therapy, helping to expand patients’ array of options when seeking IBD treatment in different countries.
....

Fang Wang , National Clinical Research Center , Digestive Diseases , Xijing Hospital , Crohns Colitis , Inflammatory Bowel Disease , Crohn X27s Disease ,

Global Biosimilars Market Analysis 2023-2028

Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) The ....

Global Biosimilars Market , Growth Opportunity , Opportunity Analysis , Middle East , Research And Markets , Iosimilars And Biosuperiors ,

Gastroenterology Month in Review: October 2023

Our gastroenterology month in review highlights multiple FDA approvals, conference coverage from ACG 2023, and other top news in gastroenterology. ....

Marla Dubinsky , Eli Lilly , National Program Of Cancer Registries , American College Of Gastroenterology , American College , Biologics License Application , Complete Response Letter , Ulcerative Colitis , Mount Sinai Kravis Children , End Results , National Program , Inflammatory Bowel Disease , Colorectal Cancer , Glp 1 , Elevate Uc ,

Proposed Biosimilar GP40141, Romiplostim Show Similar Pharmacodynamic Profiles

Findings from the phase 1 study informed the clinical development program for GP40141 as a biosimilar treatment for ITP, demonstrating pharmacodynamic similarity to reference romiplostim. ....

Researchgate Igor Makarenko , Igor Makarenko , Drug Administration , Idiopathic Thrombocytopenic , Accessed October , Subcutaneous Route , Idiopathic Thrombocytopenic Purpura , Phase 1 ,

A hard lesson learnt: Commonwealth v Sanofi

The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays generic launch but the patent is invalidated or there is a finding of non-infringement. ....

Full Federal Court , Pharmaceutical Benefits Scheme , Pearce Ip , Preliminary Injunction ,